To date, a substantial effort has been focused on targeting KIT by small molecule inhibitor imatinib, having dramatic activity against chemoresistant sarcoma and gastrointestinal stromal tumors, in which the clinical response correlates with the type of KIT mutations [45]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.